- $2.05bn
- $2.13bn
- $120.25m
Brief: FDA Accepts Mesoblast’S Biologics License Application For Ryoncil®
Brief: Mesoblast Says US FDA Accepts BLA Resubmission For Remestemcel-L
Brief: Mesoblast Ltd Says Mesoblast Resubmits BLA With FDA For Ryoncil Approval
Brief: Mesoblast Says Joseph R. Swedish Has Chosen To Transition From Chair
Australia's Mesoblast extends gain on FDA support for proposed drug licence application
Australia's Mesoblast eyes best day in 4 years on FDA support; Jefferies raises PT
Australia's Mesoblast eyes best day in 4 years on FDA support
Mesoblast climbs on FDA support for heart failure drug approval
Australia's Mesoblast rises on FDA support for heart failure drug approval
Brief: Mesoblast Says US FDA Supports Accelerated Approval Pathway For Rexlemestrocel-L
Brief: Mesoblast Posts HY Loss Attributable $32.5 Million
Mesoblast Ltd expected to post a loss of 15 cents a share - Earnings Preview
Mesoblast Ltd expected to post a loss of 15 cents a share - Earnings Preview
Mesoblast Ltd expected to post a loss of 15 cents a share - Earnings Preview
Australia's Mesoblast jumps as US FDA grants orphan-drug status to heart drug
Brief: Mesoblast Says FDA Grants Orphan Drug Designation For Revascor
Mesoblast up as FDA grants rare pediatric disease tag to cell therapy
Brief: Mesoblast Says FDA Grants Rare Pediatric Disease Designation For Revascor
Australia's Mesoblast soars after FDA grants cell therapy rare pediatric disease tag